[Localized MSI/dMMR gastric cancer patients, perioperative immunotherapy instead of chemotherapy: The GERCOR NEONIPIGA phase II study is opened to recruitment].
Fiche publication
Date publication
février 2020
Journal
Bulletin du cancer
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BORG Christophe, Dr VERNEREY Dewi
Tous les auteurs :
Cohen R, Pudlarz T, Garcia-Larnicol ML, Vernerey D, Dray X, Clavel L, Jary M, Piessen G, Zaanan A, Aparicio T, Louvet C, Tournigand C, Chibaudel B, Tougeron D, Guimbaud R, Benouna J, Adenis A, Sokol H, Borg C, Duval A, Svrcek M, André T
Lien Pubmed
Résumé
Perioperative chemotherapy is the standard strategy for localized gastric cancers. Nevertheless, this strategy seems to be inefficient, if not deleterious, for patients with tumors harboring microsatellite instability (MSI) and/or mismatch repair deficiency (dMMR), a tumor phenotype predictive for the efficacy of immune checkpoint inhibitors (ICKi).
Mots clés
Cancer de l’estomac, Gastric cancer, Instabilité des microsatellites, Ipilimumab, Lynch syndrome, Microsatellite instability, Nivolumab, Syndrome de Lynch
Référence
Bull Cancer. 2020 Feb 10;: